BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18988865)

  • 1. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
    Cornelissen JJ; van der Holt B; Verhoef GE; van't Veer MB; van Oers MH; Schouten HC; Ossenkoppele G; Sonneveld P; Maertens J; van Marwijk Kooy M; Schaafsma MR; Wijermans PW; Biesma DH; Wittebol S; Voogt PJ; Baars JW; Zachée P; Verdonck LF; Löwenberg B; Dekker AW;
    Blood; 2009 Feb; 113(6):1375-82. PubMed ID: 18988865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
    Cornelissen JJ; van Putten WL; Verdonck LF; Theobald M; Jacky E; Daenen SM; van Marwijk Kooy M; Wijermans P; Schouten H; Huijgens PC; van der Lelie H; Fey M; Ferrant A; Maertens J; Gratwohl A; Lowenberg B
    Blood; 2007 May; 109(9):3658-66. PubMed ID: 17213292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
    Kennedy-Nasser AA; Bollard CM; Myers GD; Leung KS; Gottschalk S; Zhang Y; Liu H; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1245-52. PubMed ID: 18940679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
    Mohty M; Labopin M; Volin L; Gratwohl A; Socié G; Esteve J; Tabrizi R; Nagler A; Rocha V;
    Blood; 2010 Nov; 116(22):4439-43. PubMed ID: 20716774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission.
    Pidala J; Djulbegovic B; Anasetti C; Kharfan-Dabaja M; Kumar A
    Cochrane Database Syst Rev; 2011 Oct; 2011(10):CD008818. PubMed ID: 21975786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
    Goldstone AH; Richards SM; Lazarus HM; Tallman MS; Buck G; Fielding AK; Burnett AK; Chopra R; Wiernik PH; Foroni L; Paietta E; Litzow MR; Marks DI; Durrant J; McMillan A; Franklin IM; Luger S; Ciobanu N; Rowe JM
    Blood; 2008 Feb; 111(4):1827-33. PubMed ID: 18048644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
    Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
    Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
    Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Byrne M; Volin L; Finke J; Niederwieser D; Ehninger G; Blaise D; Beelen D; Tabrizi R; Sengeloev H; Ganser A; Cornelissen JJ; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2251-2260. PubMed ID: 31271887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
    Suciu S; Mandelli F; de Witte T; Zittoun R; Gallo E; Labar B; De Rosa G; Belhabri A; Giustolisi R; Delarue R; Liso V; Mirto S; Leone G; Bourhis JH; Fioritoni G; Jehn U; Amadori S; Fazi P; Hagemeijer A; Willemze R;
    Blood; 2003 Aug; 102(4):1232-40. PubMed ID: 12714526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
    Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
    Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
    Hwang YY; Mohty M; Chim CS
    Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
    Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
    Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
    Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
    Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
    Cho BS; Lee S; Kim YJ; Chung NG; Eom KS; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim CC
    Leukemia; 2009 Oct; 23(10):1763-70. PubMed ID: 19440217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1.
    Lv M; Jiang Q; Zhou DB; Hu Y; Liu DH; Wu DP; Wang JB; Jiang H; Wang J; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2020 May; 13(1):52. PubMed ID: 32414392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.